Cover Image
市場調查報告書

人類乳突病毒E6蛋白:開發中產品分析

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 368720
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
人類乳突病毒E6蛋白:開發中產品分析 Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018
出版日期: 2018年04月17日 內容資訊: 英文 81 Pages
簡介

本報告提供以人類乳突病毒E6蛋白為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

人類乳突病毒E6蛋白 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Abion Inc
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Etubics Corp
  • Genexine Inc
  • Hookipa Biotech AG
  • Inovio Pharmaceuticals Inc
  • MedImmune LLC
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Tomegavax Inc
  • Transgene SA

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1420TDB

Summary

Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins.

The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.

Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 27 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 3 and 11 respectively.

Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Glioblastoma Multiforme (GBM), Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer and Vulvar Cancer.

The latest report Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
  • The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Human Papillomavirus Protein E6 (E6) - Overview
  • Human Papillomavirus Protein E6 (E6) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
  • Abion Inc
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Etubics Corp
  • Genexine Inc
  • Hookipa Biotech AG
  • Inovio Pharmaceuticals Inc
  • MedImmune LLC
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Touchlight Genetics Ltd
  • Transgene SA
  • Human Papillomavirus Protein E6 (E6) - Drug Profiles
  • ABN-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BVAC-C - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ETBX-041 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GX-188E - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HB-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • human papillomavirus [serotype 16] vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • human papillomavirus [serotypes 16] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • human papillomavirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INO-3106 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MEDI-0457 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SEL-701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TA-CIN - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TG-4001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tricurin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for HPV Associated Cervical Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VGX-3100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vvax-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Human Papillomavirus Protein E6 (E6) - Dormant Products
  • Human Papillomavirus Protein E6 (E6) - Discontinued Products
  • Human Papillomavirus Protein E6 (E6) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
  • Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
  • Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112
  • Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference
  • Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
  • Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer
  • Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
  • May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
  • Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
  • Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
  • Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
  • Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
  • Oct 17, 2016: Hookipa Secures EUR 4.16 Million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies
  • Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
  • Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Abion Inc, H1 2018
  • Pipeline by BioNTech AG, H1 2018
  • Pipeline by Cancer Research Technology Ltd, H1 2018
  • Pipeline by Etubics Corp, H1 2018
  • Pipeline by Genexine Inc, H1 2018
  • Pipeline by Hookipa Biotech AG, H1 2018
  • Pipeline by Inovio Pharmaceuticals Inc, H1 2018
  • Pipeline by MedImmune LLC, H1 2018
  • Pipeline by Rottapharm Biotech Srl, H1 2018
  • Pipeline by Selecta Biosciences Inc, H1 2018
  • Pipeline by Touchlight Genetics Ltd, H1 2018
  • Pipeline by Transgene SA, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top